Premium
Management of urethral recurrence after orthotopic urinary diversion
Author(s) -
Taylor Jennifer M.,
Spiess Philippe E.,
Kassouf Wassim,
Munsell Mark F.,
Kamat Ashish M.,
Dinney Colin P.N.,
Grossman H. Barton,
Pisters Louis L.
Publication year - 2010
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.09095.x
Subject(s) - medicine , urinary diversion , cystectomy , urethra , surgery , urinary system , bladder cancer , urinary bladder , urology , neck of urinary bladder , cancer
Study Type – Therapy (case series)
Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder. PATIENTS AND METHODS We retrospectively reviewed the records of patients treated with RC and orthotopic urinary diversion between January 1980 and July 2004. RESULTS In all, 260 patients underwent RC with a Studer or Hautmann orthotopic urinary diversion; the median (range) follow‐up was 5.1 (0–15.6) years. Six patients (2.3%) developed local recurrence of urothelial cancer (UC) within the urethra after this treatment. The median (range) time to presentation with recurrence after RC was 2.4 (0.7–3.6) years for pT1‐4 UC. Recurrences were treated with various methods, including transurethral resection, urethrectomy with conversion of neobladder to continent catheterizable diversion, and chemotherapy. At the last follow‐up, four of these six patients were alive without disease, one was alive with disease, and one had died from disease. CONCLUSIONS In our experience, local recurrences involving the urethra are infrequent. Complete surgical excision can provide a good outcome. Neoadjuvant chemotherapy should be considered for recurrences with adverse clinicopathological features.